ALBIO Fundamental Analysis - BIOSYNEX

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALBIO. ALBIO was compared to 59 industry peers in the Health Care Equipment & Supplies industry. ALBIO has a bad profitability rating. Also its financial health evaluation is rather negative. ALBIO has a valuation in line with the averages, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALBIO has reported negative net income.

ALBIO had a negative operating cash flow in the past year.

In multiple years ALBIO reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: ALBIO reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of ALBIO (-22.24%) is worse than 69.49% of its industry peers.

With a Return On Equity value of -53.75%, ALBIO is not doing good in the industry: 74.58% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-22.24%
ROE	-53.75%
ROIC	N/A

ROA(3y)-10.54%

ROA(5y)6.39%

ROE(3y)-24.67%

ROE(5y)7.07%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALBIO has a Gross Margin (56.78%) which is comparable to the rest of the industry.

ALBIO's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for ALBIO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	56.78%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.7%

GM growth 5Y-0.09%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALBIO has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for ALBIO has been increased compared to 5 years ago.

ALBIO has a worse debt/assets ratio than last year.

2.2 Solvency

ALBIO has an Altman-Z score of 0.26. This is a bad value and indicates that ALBIO is not financially healthy and even has some risk of bankruptcy.

ALBIO has a worse Altman-Z score (0.26) than 69.49% of its industry peers.

A Debt/Equity ratio of 0.19 indicates that ALBIO is not too dependend on debt financing.

ALBIO has a Debt to Equity ratio of 0.19. This is in the better half of the industry: ALBIO outperforms 72.88% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.19
Debt/FCF	N/A
Altman-Z	0.26

ROIC/WACCN/A

WACC6.55%

2.3 Liquidity

ALBIO has a Current Ratio of 0.71. This is a bad value and indicates that ALBIO is not financially healthy enough and could expect problems in meeting its short term obligations.

ALBIO's Current ratio of 0.71 is on the low side compared to the rest of the industry. ALBIO is outperformed by 86.44% of its industry peers.

A Quick Ratio of 0.35 indicates that ALBIO may have some problems paying its short term obligations.

With a Quick ratio value of 0.35, ALBIO is not doing good in the industry: 88.14% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.71
Quick Ratio	0.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ALBIO have decreased strongly by -12.27% in the last year.

The Revenue has grown by 8.76% in the past year. This is quite good.

The Revenue has been growing by 24.22% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-12.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-22.69%

Revenue 1Y (TTM)8.76%

Revenue growth 3Y-35.81%

Revenue growth 5Y24.22%

Sales Q2Q%-5.76%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y475%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year15.05%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Based on the Price/Forward Earnings ratio of 2.53, the valuation of ALBIO can be described as very cheap.

Based on the Price/Forward Earnings ratio, ALBIO is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.

When comparing the Price/Forward Earnings ratio of ALBIO to the average of the S&P500 Index (22.19), we can say ALBIO is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	2.53

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALBIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALBIO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOSYNEX

EPA:ALBIO (6/17/2025, 7:00:00 PM)

1.2

-0.03 (-2.44%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)10-19 2024-10-19

Earnings (Next)N/A N/A

Inst Owners0.46%

Inst Owner ChangeN/A

Ins Owners5.7%

Ins Owner ChangeN/A

Market Cap22.50M

Analysts86.67

Price Target12.85 (970.83%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	2.53
P/S	0.22
P/FCF	N/A
P/OCF	N/A
P/B	0.28
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-3.37

EYN/A

EPS(NY)0.47

Fwd EY39.48%

FCF(TTM)-0.8

FCFYN/A

OCF(TTM)-0.54

OCFYN/A

SpS5.39

BVpS4.3

TBVpS-1.73

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-22.24%
ROE	-53.75%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	56.78%
FCFM	N/A

ROA(3y)-10.54%

ROA(5y)6.39%

ROE(3y)-24.67%

ROE(5y)7.07%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.7%

GM growth 5Y-0.09%

F-Score4

Asset Turnover0.52

Health

		Industry Rank	Sector Rank
Debt/Equity	0.19
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	23.57%
Cap/Sales	4.79%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.71
Quick Ratio	0.35
Altman-Z	0.26

F-Score4

WACC6.55%

ROIC/WACCN/A

Cap/Depr(3y)143.09%

Cap/Depr(5y)301.13%

Cap/Sales(3y)20.88%

Cap/Sales(5y)14.7%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-12.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-22.69%

EPS Next Y475%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)8.76%

Revenue growth 3Y-35.81%

Revenue growth 5Y24.22%

Sales Q2Q%-5.76%

Revenue Next Year15.05%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y5.07%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year2216.67%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y69.59%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-4.84%

OCF growth 3YN/A

OCF growth 5YN/A

BIOSYNEX (ALBIO.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens